Report Highlights
Including: 1) By Type: Renal Cell Carcinoma; Urothelial Carcinoma
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin)
3) By End Users: Hospitals; Clinics; Research Center
Covering: Bayer AG; Pfizer Inc.; Novartis International AG; Exelixis Inc.; F. Hoffmann-La Roche Ag
Kidney Cancer Drugs Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on kidney cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for kidney cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2022-2032 |
| Units considered | $ Billion |
| Segments covered | By Type, By Product, By End Users |
| Industry covered | Pharmaceuticals |
| Regions covered | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Countries covered | Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA |
| Companies studied |
|
Scope
Markets Covered:
- By Type: Renal Cell Carcinoma; Urothelial Carcinoma; Others (Renal Sarcoma, Renal Lymphoma)
- By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin); Other Products
- By End Users: Hospitals; Clinics; Research Center; Other End-Users
Companies Mentioned: Bayer AG; Pfizer Inc; Novartis International AG; Exelixis Inc; F. Hoffmann-La Roche Ag
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
- Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Table 3 : Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 4 : Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 5 : Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 6 : Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 7 : Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 8 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 9 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 10 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 11 : China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 12 : China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 13 : China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 14 : India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 15 : India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 16 : India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 17 : Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 18 : Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 19 : Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 20 : Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 21 : Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 22 : Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 23 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 24 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 25 : Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 26 : South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 27 : South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 28 : South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 29 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 30 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 31 : Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 32 : UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 33 : UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 34 : UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 35 : Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 36 : Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 37 : Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 38 : France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 39 : France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 40 : France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 41 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 42 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 43 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 44 : Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 45 : Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 46 : Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 47 : North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 48 : North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 49 : North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 50 : USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 51 : USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 52 : USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 53 : South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 54 : South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 55 : South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 56 : Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 57 : Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 58 : Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 59 : Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 60 : Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 61 : Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 62 : Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 63 : Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 64 : Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Table 65 : Bayer AG Financial Performance
- Table 66 : Pfizer Inc Financial Performance
- Table 67 : Novartis International AG Financial Performance
- Table 68 : Exelixis, Inc Financial Performance
- Table 69 : F. Hoffmann-La Roche Ag Financial Performance
- Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
- Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
- Figure 3 : Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 4 : Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 5 : Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 6 : Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 7 : Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 8 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 9 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 10 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 11 : China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 12 : China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 13 : China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 14 : India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 15 : India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 16 : India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 17 : Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 18 : Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 19 : Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 20 : Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 21 : Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 22 : Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 23 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 24 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 25 : Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 26 : South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 27 : South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 28 : South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 29 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 30 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 31 : Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 32 : UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 33 : UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 34 : UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 35 : Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 36 : Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 37 : Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 38 : France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 39 : France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 40 : France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 41 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 42 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 43 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 44 : Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 45 : Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 46 : Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 47 : North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 48 : North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 49 : North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 50 : USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 51 : USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 52 : USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 53 : South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 54 : South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 55 : South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 56 : Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 57 : Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 58 : Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 59 : Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 60 : Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 61 : Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 62 : Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 63 : Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 64 : Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Figure 65 : Bayer AG Financial Performance
- Figure 66 : Pfizer Inc Financial Performance
- Figure 67 : Novartis International AG Financial Performance
- Figure 68 : Exelixis, Inc Financial Performance
- Figure 69 : F. Hoffmann-La Roche Ag Financial Performance
The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Similar Reports from TBRC (Publisher)
Kidney Cancer Drugs Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change
Including: 1) By Type: Renal Cell Carcinoma (RCC); Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Other Products
3) By End Users: Hospitals; Clinics; Research Center; Other End-Users
Covering: Pfizer Inc.; Novartis AG; Exelixis; Inc.; F. Hoffmann-La Roche AG; Bristol Myers Squibb Company
Kidney ...
Kidney Cancer Drugs Global Market Report 2022
Including: 1) By Type: Renal Cell Carcinoma; Urothelial Carcinoma; Others (Renal Sarcoma, Renal Lymphoma)
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin); Others
3) By End Users: Hospitals; Clinics; Research Center; Others
Covering: Bayer AG; Pfizer Inc.; Novartis International AG; Exelixis Inc.; F. Hoffmann-La Roche Ag; Genentech Inc.; Glaxosmithkline ...
Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030
Including: 1) By Type: Renal Cell Carcinoma (RCC); Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin); Others
3) By End Users: Hospitals; Clinics; Research Center; Others
Covering: Bayer AG; Pfizer Inc; Novartis International AG; Exelixis; F. Hoffmann-La Roche Ag
Kidney ...
Kidney Cancer Drugs Global Market Report 2020
Including: 1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC) 2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib),, Torisel (Temsirolimus), Proleukin (Aldesleukin), Others 3) By End Users: Hospitals, Clinics, Research Center, Others
Covering: Bayer AG, Pfizer Inc, Novartis International AG, Exelixis, Inc, F. Hoffmann-La Roche Ag
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More